Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 448Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Breast Neoplasms 161Triple Negative Breast Neoplasms 160Neoplasm Metastasis 155Lung Neoplasms 140Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 100Carcinoma, Transitional Cell 91Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 72Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Glioblastoma 39Carcinoma, Squamous Cell 39Small Cell Lung Carcinoma 38Hodgkin Disease 36Lymphoma 34

Interventions

Paclitaxel 4liposomal doxorubicin 3Carboplatin 3pembrolizumab 2Bevacizumab 21-dodecylpyridoxal 2poly(I).poly(c12,U) 1mirabegron 1disitamab vedotin 1apatinib 1anlotinib 1Tocotrienols 1Platinum Compounds 1Lenalidomide 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1EP-100 membrane-disrupting peptide 1Cisplatin 1AC 7700 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Ovarian Cancer Recurrent × pembrolizumab × Clear all
NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
460 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

University of Pittsburgh

Phase 1/2 Active not recruiting
24 enrolled 59 charts
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡